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introduction: Infections by certain viruses, bacteria, and parasites have been identi-
fied as risk factors for some cancers. In Nigeria, like many other developing countries, 
infections remain a leading cause of morbidity and mortality. While there are data on the 
incidence of different cancers in Nigeria, there has been no study of cancers attributable 
to infections. This study was carried out to determine the burden of cancers attributable 
to infections using data from two population-based cancer registries (PBCRs) in Nigeria.
Methods: We obtained data on cancers associated with EBV, human papillomavirus 
(HPV), hepatitis B and C, HIV, HHV8, Helicobacter pylori, and Schistosoma spp. from 
the databases of Abuja and Enugu cancer registries in Nigeria. We used population- 
attributable fraction for infections-associated cancers in developing countries that are 
based on prevalence data and relative risk estimates from previous studies.
results: The PBCRs reported 4,336 incident cancer cases [age standardized incidence 
rate (ASR) 113.9 per 100,000] from 2012 to 2014, of which 1,627 (37.5%) were in 
males and 2,709 (62.5%) were in females. Some 1,030 (23.8%) of these cancers were 
associated with infections (ASR 44.4 per 100,000), while 951 (22.0%) were attributable 
to infections (ASR 41.6 per 100,000). Cancers of the cervix (n = 392, ASR 28.3 per 
100,000) and liver (n =  145, ASR 3.4 per 100,000); and non-Hodgkin’s lymphoma 
(n = 110, ASR 2.5 per 100,000) were the commonest infections-associated cancers 
overall. The commonest infectious agents associated with cancers in this population 
were HPV, EBV, hepatitis B and C, HIV, and HHV8.
conclusion: Our results suggest that 23.8% of incident cancer cases in this popu-
lation were associated with infections, while 22.0% were attributable to infections. 
The  infections attributable cancers are potentially preventable with strategies, such as 
vaccination, risk factor modification, or anti-infective treatment.
Keywords: cancers, infectious agents, population-attributable fraction, cancer registry, nigeria
TaBle 1 | list of group 1 carcinogenic biological agents and related 
cancers.
infections-associated 
cancers
group 1 agents
Cervix Human papillomavirus
Vulva Human papillomavirus
Vagina Human papillomavirus
Anus Human papillomavirus
Oropharynx Human papillomavirus
Bladder Schistosoma haematobium
Liver Hepatitis B virus/hepatitis C virus
Nasopharynx Epstein–Barr virus
Stomach Helicobacter pylori
Non-Hodgkin lymphoma Epstein–Barr virus/human immunodeficiency 
virus type-1
Hodgkin lymphoma Epstein–Barr virus
Kaposi sarcoma Human herpesvirus 8/human immunodeficiency 
virus type-1
Penis Human papillomavirus
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inTrODUcTiOn
Infectious agents are important contributors to the global 
cancer burden particularly in Africa. Of the 12.7 million new 
cancer cases that were diagnosed worldwide in 2008, about two 
million (16.1%) were attributable to infectious agents, of which 
1.6 million occurred in less developed regions of the world (1). 
In its 2009 review of the carcinogenicity of infectious agents, 
the International Agency for Research on Cancer (IARC) 
found sufficient evidence to conclude that seven viruses: 
human papillomavirus (HPV), Epstein–Barr virus, hepatitis 
B virus (HBV), hepatitis C virus (HCV), human immunode-
ficiency virus type-1 (HIV-1), Kaposi’s sarcoma herpes virus 
(KSHV), and human T-cell leukemia virus type-1 (HTLV-1), 
the bacterium Helicobacter pylori, and the parasites Clonorchis 
sinensis (C. sinensis), Opisthorchis viverrini (C. sinensis), and 
Schistosoma haematobium (S. haematobium) were carcinogenic 
to humans (2).
The proportion of cancers attributable to infections in devel-
oping countries has been estimated to vary between 20 and 30% 
which contrasts with 3–10% in developed countries (1, 3–5). 
Although there are estimates of the burden of infection-associ-
ated cancers based on cancer registry data for countries, such 
as Australia (3), United Kingdom (4), Netherlands (5), United 
States (6), South Korea (7), France (8), and China (9), there are 
no country-specific estimates for countries in Africa, including 
Nigeria. It is important to quantify the proportion of the cancer 
burden that could be prevented by the implementation of effec-
tive interventions that limit exposure to the infections-associated 
with cancers, particularly in Africa.
Since the resuscitation and strengthening of cancer registra-
tion in Nigeria starting 2009, more population-based cancer 
registries (PBCRs) have become operational (10–12). The aim 
of this study is to estimate the burden of cancers attributable 
to infections in Nigeria between 2012 and 2014 from these 
PBCRs.
MaTerials anD MeThODs
Data sources
We retrieved cancer incidence information from two PBCRs in 
Nigeria, the Abuja and Enugu cancer registries, for the period 
2012–2014. The Abuja Cancer Registry (ABCR), established in 
2009, has a catchment area that covers the entire federal capital 
territory and a population of 1,406,239 people (10). The Enugu 
Cancer Registry (ECR) was established in 2012 and covers an 
area around the greater Enugu city metropolis with a population 
of 1,103,153 people (12). The registries utilize the International 
Classification of Disease for Oncology, 3rd Edition (ICD-O3) for 
coding and classification of cancers. The ABCR uses CanReg4 
software for storing and processing data, while the ECR uses 
CanReg5. Approval for cancer registration activities and research 
was obtained from the National Health and Research Ethics 
Committee of Nigeria (NHREC). Anonymity and confidentiality 
were maintained in all analyses and publications derived from the 
cancer registry data.
Data handling and statistical analysis
Data checks were done by Michael Kolawole Odutola and Elima 
E. Jedy-Agba using the IARC CanReg5 software. We performed 
quality control checks to remove duplicates, and to ensure logical 
correctness and overall accuracy of the data. Analysis of incident 
cancer cases and age standardized incidence rate (ASR) calcula-
tion was generated by the CanReg5 software.
For this analysis, we retrieved age and sex-specific number 
of incident cancers reported by the cancer registries during the 
period under study. Using the classification of carcinogens by 
IARC in monograph 100b, we identified the following cancers 
considered to be associated with infectious agents in humans: 
nasopharygeal (C11), oropharyngeal (C01, C09, C10), stom-
ach (C16), liver (C22), bladder (C67), Hodgkin lymphoma 
(HL; C81), non-Hodgkin lymphoma (NHL; C82–C85; C96), 
Kaposi Sarcoma (KS) (C46), and anal cancers (C21) in both 
sexes; cervical (C53), vulvar (C51), and vaginal cancers (C52) 
in females; and penile cancer (C60) in males (Table 1). We con-
sidered all the infectious agents identified by IARC as Group 
1 carcinogens, except Human T-cell leukemia virus type-1 
(HTLV-1); C. sinensis and O. viverrini associated with acute 
T-cell leukemia/lymphoma and cancer of the bile duct, 
respectively, because of the rarity of these cancers in African 
populations (13).
We used the standard formula for population-attributable 
fraction (PAF) (4):
 PAF ( 1) / ( 1) 1[ ]= −p r p r− +  
where r represents the relative risk of exposure and p its preva-
lence in the population. The application of this formula requires 
information about the prevalence of the exposure to the infectious 
agents in the population, as well as the corresponding relative 
risks. In previous studies, this method was used to estimate the 
number of cancers attributable to HBV, HCV, H. pylori, and HIV. 
For HPV and EBV, the PAF was assumed to be equivalent to the 
prevalence of viral DNA in the tumor cells.
TaBle 2 | Previous prevalence studies on infectious agents and cancer.
infectious 
agent
cancer site icD-O code Prevalence of infectious agents 
in cancers (ssa population) (%)
studies in african populations PaF estimates used 
in this study %
HPV Cervix C53 83–98 Nigeria, South-Africa (14), Ghana (15) 100 (16)
Vulva C51 100 Botswana (17) 40 (18)
Vagina C52 – None 40–70 (13, 18)
Anus C21 88 Nigeria, Mali, Senegal (19) 88–90 (13, 19)
Oropharynx C01–C02; C09–C10 19 Ghana (20) 12–46 (13, 21)
Penis C60 68 Kenya (22) 40–48 (13, 23)
Shistosoma Bladder C67 – None 56 (13)
HBV/HCV Liver C22 74–77 Nigeria (24), Gambia (25) 92 (13)
H. pylori Stomach C16 56–86 Nigeria (26), Uganda (27) 74 (13)
EBV Nasopharynx C11 – None 100 (13, 28)
HL C81 55 Nigeria (29) 80 (13)
EBV/HIV NHL C82–C85; C96 80–95 Nigeria (29), Uganda (30) 100 (13)
HIV/HHV8 KS C46 83 Nigeria, Benin, Côte d’Ivoire, Togo (31) 100 (32, 33)
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In this study, we used the PAF for infectious agents associ-
ated with cancers that are derived from prevalence and risk 
estimates from developing countries (Table 2). We did not have 
PAF from Nigeria because of the absence of rigorous and robust 
measures of relative risk for the different infectious agents in 
this population. Additionally, data on prevalence of exposure 
to most of the infectious agents is scanty. The few prevalence 
studies from Nigeria had relatively small sample sizes (less than 
50) and were not population based. For each infectious agent, 
we estimated the number of new cancer cases attributable to 
that infection by multiplying the overall numbers of cancer 
cases reported per cancer site with the PAF estimates extracted 
from meta-analyses.
In determining PAF estimates for cervical cancer, we identi-
fied other studies from Africa that reported the prevalence of 
HPV in cervical tumor cells to be between 83 and 98% (14, 15). 
However, we used a PAF of 100% because it is established that 
HPV is a necessary cause of cervical cancer (16, 34). For vulvar 
cancer, we found a Botswanan study with a sample size of 35 
which reported an HPV prevalence of 100% (17). However, we 
used a PAF estimate of 40% obtained from meta-analyses for 
developing countries, because of the small sample size used in 
that study (13). We did not find any African regional study on 
the prevalence of HPV in vaginal cancer, hence, we used a PAF 
estimate of 40–70% from meta-analyses of studies from develop-
ing countries (13, 18). Because we did not find any individual 
study on HPV prevalence in anal cancer from Africa, we used a 
PAF estimate of 88–90% from meta-analyses that included cases 
from developing countries, including Nigeria, Mali, and Senegal 
(13, 19). A study from Ghana showed HPV prevalence of 16% 
in etiology of oropharyngeal cancer (OPC) (20), while a study 
evaluating HPV prevalence in oropharyngeal, and other head 
and neck cancers in Nigeria had suboptimal sample size and 
poor tissue sample quality (35); hence, we used PAF estimate of 
12–46% from meta-analyses of studies from developing coun-
tries (13, 21). The prevalence of HPV in 22 penile cancer cases 
from Kenya was found to be 68.2% (22). As a result of the small 
sample size, we used a worldwide estimated PAF of 40–48% from 
meta-analyses (13, 23).
We used a PAF estimate of 56% for bladder cancer associated 
with S. haematobium from a meta-analysis for West-African 
countries (13). Although, we identified two studies from Nigeria 
and Gambia that reported the prevalence of HBV and HCV in 
liver cancer to range from 74 to 77% (24, 25), we used a PAF 
estimate of 92% from a meta-analysis of studies from developing 
countries (13). Two studies from Nigeria and Uganda evaluated 
the prevalence of H. pylori in stomach cancer to be 72–87% (26, 
27); however, we used an estimated PAF of 74% from a meta-
analysis of studies from developing countries (13). We did not 
find any studies of the prevalence of EBV in nasopharyngeal can-
cer in SSA, we used a PAF estimate of 100% from a meta-analysis 
of studies from developing countries (13, 28). For NHL in HIV 
infections, although we identified two studies from Nigeria and 
Uganda with prevalence ranging from 80 to 95% (29, 30), we used 
an estimated PAF of 100% based on meta-analysis of studies from 
developing countries because of the limited sample size of 44 used 
in the Nigerian study (13). The prevalence of EBV infection in 
Hodgkin’s Lymphoma from a Nigerian study was 55% (29) but 
the small sample size (11) was small so we used estimated PAF 
of 80% derived from a meta-analysis of studies from developing 
countries (13). HHV8 is recognized as a necessary cause of KS in 
HIV infections; therefore, we used PAF of 100% for KS (31–33).
We carried out sensitivity analyses for cancers attributable 
to infections, using GLOBOCAN 2012 database for Nigeria. 
GLOBOCAN 2012 database contains incidence estimates for 
only 7 (cancer of the liver, cervix, nasopharynx, bladder; HL, 
NHL; and KS) out of the 12 infections-associated cancers that we 
evaluated in our analyses.
resUlTs
Overview
Over a 3-year period from 2012 to 2014, the Abuja and Enugu 
PBCRs reported 4,336 cancer cases [1,627 (37.5%) in males, 
2,709 (62.5%) in females]. In total, 1,030 (23.8%) cancer cases 
were associated with infections (Table 3). The ASR of infections-
associated cancers was 44.4 per 100,000. Approximately 90% 
(328 of 365) and 94% (623 of 665) of these infections-associated 
TaBle 3 | Total number of cancer cases associated with infections in 
nigeria from 2012 to 2014.
sex cancer site icD-O code no. of cancer 
cases
% of total 
cancer
asr
Female Cervix C53 392 30.0 28.3
Vulva C51 25 1.8 1.3
Vagina C52 8 0.6 0.4
Anus C21 17 1.3 0.7
Oropharynx C01–C02; C09–C10 8 0.6 0.5
Bladder C67 14 1.1 1.1
Liver C22 52 3.9 2.7
Nasopharynx C11 34 2.5 1.5
Stomach C16 23 1.7 1.4
NHL C82–C85; C96 49 3.7 2.3
HL C81 17 1.2 0.5
KS C46 26 2.0 1.1
Male Penis C60 2 0.2 0.1
Anus C21 21 2.7 1.4
Oropharynx C01–C02; C09–C10 15 1.9 0.8
Bladder C67 30 3.8 1.4
Liver C22 93 11.9 4.0
Nasopharynx C11 47 6.1 1.7
Stomach C16 33 4.4 1.7
NHL C82–C85; C96 61 7.6 2.7
HL C81 28 8.7 1.0
KS C46 35 4.6 1.3
Total 1,030 23.8 44.4
4
Odutola et al. Infections-Attributable Cancers in Nigeria
Frontiers in Oncology | www.frontiersin.org October 2016 | Volume 6 | Article 216
cancers were attributable to infections in males and females, 
respectively (Table 4). Of all the infections-associated cancers 
reported, 22.0% (951 of 4,336) were attributable to infections. 
The ASR for infections-attributable cancers was 41.6 per 
100,000. Cancers attributable to infections constituted 20.2% 
(328 of 1,627) of cases in males and 23.0% (623 of 2,709) in 
females (Table 4).
In 2012, GLOBOCAN estimated that 102,079 [64,709 (63.3%) 
in women, 37,370 (36.6%) in men] cancer cases occurred 
in Nigeria. In total, 35.9% were associated with infections. 
The ASR for infections-associated cancers in Nigeria from 
the GLOBOCAN 2012 database was 50.0 per 100,000. Of all the 
infections-associated cancers reported, 33.8% were attributable 
to infections. The ASR for infections-attributable cancers in 
GLOBOCAN 2012 was 47.4 per 100,000 (Table 5).
cervical cancer and hPV
Cervical cancer was the commonest infections-associated 
cancer reported by ABCR and ECR within the study period. 
A total of 392 cases were reported, representing 30% of all can-
cers in females (Table 3). The ASR for cervical cancer was 28.3 
per 100,000 (Table 3). The highest numbers of cervical cancer 
cases were seen in the 45 to 54 years age groups (110 cases), and 
ages 65  years and above (98 cases). Using a PAF of 100% for 
cervical cancer cases, we conclude that all 392 cervical cancer 
cases reported within the study period were attributable to HPV 
infection, with attributable ASR of 28.3 per 100,000 (Table 4).
Vulvar cancer and hPV
There were 25 vulvar cancer cases reported by the PBCRs from 
2012 to 2014 representing 1.8% of all female cancers and an ASR 
of 1.3 per 100,000 (Table 3). About half of the vulvar cancer cases 
were seen in the 45 to 54  years age group. Using PAF of 40% 
from a meta-analysis (18), 10 of the 25 cases were attributable 
to HPV infection yielding an attributable ASR of 0.5 per 100,000 
(Table 4).
Vaginal cancer and hPV
Eight vaginal cancer cases were reported by both registries, 
constituting 0.6% of female cancers in the study period with an 
ASR of 0.4 per 100,000 (Table 3). Three to six of the eight vaginal 
cancer cases were attributable to HPV infection, using a PAF of 
40–70% (13, 18). The ASR for vaginal cancers attributable to HPV 
infection ranged from 0.2 to 0.3 per 100,000 (Table 4).
anal cancer and hPV
There were 38 anal cancer cases reported by the ABCR and ECR 
from 2012 to 2014. Seventeen cases were reported in females, rep-
resenting 1.3% of female cancers and 21 cases reported in males, 
accounting for 2.7% of male cancers (Table  3). The combined 
ASR was 1.1 per 100,000 with ASR of 0.7 per 100,000 for females 
and 1.4 per 100,000 for males (Table 3). In our study, anal cancer 
was the most common HPV-associated cancer in males. Most of 
the anal cancer cases were seen between the age groups 35 and 
54 years (19 cases) in both sexes. Using a PAF of 88 to 90% (13, 
19), we estimated that 33 anal cancers in both sexes were attribut-
able to HPV. The combined ASR for anal cancers attributable to 
HPV infection was 0.9 per 100,000; 1.2 per 100,000 in males and 
0.6 per 100,000 in females (Table 4).
Oropharyngeal cancer and hPV
Some 23 oropharyngeal cancer (OPC) were reported by the 
registries from 2012 to 2014 with 8 cases in males, representing 
1.9% of male cancers and 15 cases in females, constituting 0.6% 
of female cancers (Table 3). The combined ASR for OPC was 0.7 
per 100,000, with 0.8 per 100,000 in males, and 0.5 per 100,000 
females, respectively (Table  3). Using a PAF estimate of 12 to 
46% (13, 21), we found that 3 to 11 of the 23 OPC in both sexes 
were attributable to HPV infection. The combined ASR for OPC 
attributable to HPV infection ranged from 0.1 to 0.4 per 100,000; 
0.1 to 0.4 per 100,000 for males and 0.0 to 0.3 per 100,000 for 
females (Table 4).
Penile cancer and hPV
Two cases of penile cancers were reported by the registries. Of 
these two cases, one penile cancer case was attributable to HPV 
infection using a PAF of 48% (13, 23). The ASR for penile cancer 
attributable to HPV was 0.1 per 100,000 (Table 4).
Bladder cancer and schistosoma
The two registries reported 44 cases of bladder cancers in the study 
period. More cases were reported in males (30 cases) compared to 
females (14 cases). The combined ASR was 1.3 per 100,000, with 
ASR of 1.4 per 100,000 and 1.1 per 100,000 in males and females, 
respectively. Using a PAF estimate of 56% (13), we estimated that 
25 bladder cancer cases were attributable to Schistosoma infec-
tion, with combined ASR of 0.7 per 100,000; 0.8 per 100,000 in 
men and 0.6 per 100,000 in women (Table 4).
TaBle 4 | Population-attributable fraction (PaF) and estimated numbers of cancers attributable to infectious agents in nigeria from 2012 to 2014.
infectious agent cancer site icD-O3 code no. of cancer  
cases
asr PaF % cancer cases attributable  
to infections
asr
Female
HPV Cervix C53 392 28.3 100 392 28.3
Vulva C51 25 1.3 40 10 0.5
Vagina C52 8 0.4 40–70 3–6 0.2–0.3
Anus C21 17 0.7 88–90 15 0.6
Oropharynx C01–C02; C09–C10 8 0.5 12–46 1–4 0–0.3
HBV/HCV Liver C22 52 2.7 92 48 2.5
EBV Nasopharynx C11 34 1.5 100 34 1.5
HL C81 17 0.5 80 14 0.4
EBV/HIV NHL C82–C85; C96 49 2.3 100 49 2.3
HIV/HHV8 KS C46 26 1.1 100 26 1.1
H. pylori Stomach C16 23 1.4 74 17 1.0
Schistosoma Bladder C67 14 1.1 57 8 0.6
Total (% of female cancers) 665 (25.0%) 41.8 623 (23.0%) 39.0–39.4
Male
HPV Penis C60 2 0.1 40–48 1 0.1
Anus C21 21 1.4 88 18 1.2
Oropharynx C01–C02; C09–C10 15 0.8 12 2–7 0.1–0.4
HBV/HCV Liver C22 93 4.0 92 86 3.7
EBV Nasopharynx C11 47 1.7 100 47 1.7
HL C81 28 1.8 80 22 1.4
EBV/HIV NHL C82–C85; C96 61 2.7 100 61 2.7
HIV/HHV8 KS C46 35 1.3 100 35 1.3
H. pylori Stomach C16 33 1.7 74 24 1.2
Schistosoma Bladder C67 30 1.4 57 17 0.8
Total (% of male cancers) 365 (22.4%) 16.9 328 (20.2%) 14.2–14.5
Total (% of cancers in both sexes) 1,030 (23.8%) 44.4 951 (22.0%) 41.2–41.6
TaBle 5 | sensitivity analyses of cancers attributable to infectious agents in nigeria from glOBOcan 2012 database.
infectious agent cancer site icD-O3 code no. of cancer 
cases
asr PaF % cancer cases attributable  
to infections
asr
Female
HPV Cervix C53 14,089 29.0 100 14,089 29.0
Vulva C51 NA NA NA NA NA
Vagina C52 NA NA NA NA NA
Anus C21 NA NA NA NA NA
Oropharynx C01–C02; C09–C10 NA NA NA NA NA
HBV/HCV Liver C22 4,172 8.1 92 3,838 7.5
EBV Nasopharynx C11 406 0.6 100 406 0.6
HL C81 345 0.5 80 276 0.4
EBV/HIV NHL C82–C85; C96 1,778 2.8 100 1,778 2.8
HIV/HHV8 KS C46 635 0.8 100 635 0.8
H. pylori Stomach C16 1,014 2.0 74 750 1.5
Schistosoma Bladder C67 523 0.7 57 298 0.4
Total (% of female cancers) 22,962 (35.5%) 44.5 22,084 (34.1%) 43.0
Male
HPV Penis C60 NA NA NA NA NA
Anus C21 NA NA NA NA NA
Oropharynx C01–C02; C09–C10 NA NA NA NA NA
HBV/HCV Liver C22 7,875 15.0 92 7,245 13.8
EBV Nasopharynx C11 656 1.1 100 656 1.1
HL C81 559 0.8 80 447 0.6
EBV/HIV NHL C82–C85; C96 2,328 3.7 100 2,328 3.7
HIV/HHV8 KS C46 812 1.3 100 812 1.3
H. pylori Stomach C16 875 2.0 74 648 1.5
Schistosoma Bladder C67 574 1.3 57 327 0.7
Total (% of male cancers) 13,679 (36.6%) 25.2 12,463 (33.4%) 22.7
Total (% of cancers in both sexes) 36,641 (35.9%) 50.0 34,547 (33.8%) 47.4
NA means data not available.
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liver cancer and hBV/hcV
A total of 145 liver cancer cases were reported in both sexes from 
2012 to 2014 by ABCR and ECR. Of these, 52 cases occurred in 
females and 93 cases were seen in males (Table 3). Liver cancer 
was the most common infections-associated cancer in males, 
representing 11.9% of male cancers. In females, liver cancer was 
the second most common infections-associated cancer consti-
tuting 3.9% of all female cancers reported by the PBCRs. The 
combined ASR for liver cancer was 3.4 per 100,000, with 4.0 per 
100,000 in males and 2.7 per 100,000 in females, respectively 
(Table 3). Liver cancer was most commonly seen in the 25 to 
34 and 35 to 44 years age groups with 37 cases, each in females. 
In males, liver cancer cases were commoner among the 25 to 
34  years age group with 23 cases. Using the PAF estimate of 
92% (13), we estimated that 134 cases of the 145 liver cancer 
cases reported were attributable to HBV/HCV infection with 
combined ASR of 3.1 per 100,000; 2.5 per 100,000 in males and 
3.7 per 100,000 in females (Table 4).
stomach cancer and Helicobacter pylori
There were 56 cases of stomach cancers reported in our study 
with 23 cases in females and 33 cases in males (Table 3). Stomach 
cancer accounted for 1.7% of all female cancers and 4.4% of all 
male cancers reported by the ABCR and ECR from 2012 to 2014 
(Table 3). The combined ASR was 1.6 per 100,000, with 1.4 per 
100,000 in females and 1.7 per 100,000 in males. Stomach cancer 
was more common among the 45 to 54 years age groups in both 
sexes, with 13 cases in females and 11 cases in males. Using a PAF 
estimate of 74% (13), we estimated that 41 cases of the 56 cases 
of stomach cancer were attributable to H. pylori infection, with 
combined ASR of 1.1 per 100,000; 1.2 per 100,000 in males and 
1.0 per 100,000 in females (Table 4).
nasopharyngeal cancer and eBV
The PBCRs reported 81 nasopharyngeal cancer cases in both 
sexes from 2012 to 2014. Thirty-four cancer cases were seen 
in females, representing 2.5% of female cancers and 47 cancer 
cases in males, constituting 6.1% of male cancers (Table 3). The 
combined ASR was 1.6 per 100,000, with 1.5 per 100,000 in 
females and 1.7 per 100,000 in males. Nasopharyngeal cancer 
was more common in males in the 45 to 54  years age group 
with 18 cases, while in females, it was most common among 
the 45 to 54 and 55 to 64 years age groups with 13 and 14 cases, 
respectively. We used a PAF estimate of 100% because EBV has 
been shown to be a necessary cause of nasopharyngeal cancer 
(13, 28) and assumed that all 81 nasopharyngeal cancers were 
attributable to EBV infection (Table  3). The combined ASR 
for nasopharyngeal cancers attributable to EBV infection was 
1.6 per 100,000; 1.7 per 100,000 in males and 1.5 per 100,000 
females (Table 4).
hodgkin lymphoma and eBV
Some 45 HL cases were reported by ABCR and ECR within the 
study period. Of these, 17 cases occurred in females and 28 cases 
in males (Table 3). The combined ASR was 0.8 per 100,000, with 
0.5 per 100,000 in females and 1.0 per 100,000 in males. The 
highest numbers of HL cases were reported in the 25 to 34 years 
age groups in both sexes with 13 cases. In our study, we calcu-
lated the EBV-attributable fraction for HL using a PAF estimate 
of 80% from a study by Lynnette et al. and a meta-analysis (29, 
30). Thirty-six of the 45 HL cases reported by the PBCRs were 
attributable to EBV. The combined ASR for HL attributable to 
EBV infection was 1.0 per 100,000; 0.4 per 100,000 in females and 
1.4 per 100,000 in males (Table 4).
non-hodgkin lymphoma and eBV/hiV
The registries reported 110 cases of NHL from 2012 to 2014. Forty-
nine cases were seen in females and 61 cases in males (Table 3). 
NHL was the second most common infection-associated cancer 
reported in males. The combined ASR was 5.0 per 100,000, with 
2.3 per 100,000 in females and 2.7 per 100,000 in males. We used a 
PAF of 100% as sero-epidemiological studies have shown a strong 
association of NHL with EBV (13). We estimated that 110 cases 
reported by the registries were attributable to EBV and HIV, with 
combined ASR of 2.5 per 100,000; 2.3 per 100,000 in females and 
2.7 per 100,000 in males (Table 4).
Kaposi sarcoma and hiV/hhV8
The combined ASR for KS reported by the PBCR was 2.4 per 
100,000, with 1.1 per 100,000 in males and 1.3 per 100,000 
in females (Table  3). There were 61 cases reported from 2012 
to 2014. Of these, 26 cases occurred in females representing 
2.0% of all female cancers, while 28 cases were seen in males 
accounting for 4.6% of all male cancers (Table  3). We found 
the highest number of KS cases in both sexes in the 35 to 
44  years and 45 to 54  years age groups with 24 cases each. 
We used a PAF estimate of 100% in our study because studies 
have shown that HHV8 and KS in HIV positive individuals is 
an AIDS defining cancer (32, 36). Therefore, we assume that 
all 61 cases of KS reported by the PBCRs in 2012–2014 were 
attributable to HIV/HHV8 infection with combined ASR of 1.2 
per 100,000, with 1.1 per 100,000 in males and 1.3 per 100,000 
in females (Table  4).
DiscUssiOn
In this study, we found that almost a quarter of cancer cases 
(23.8%) in these two PBCR were associated with infections 
and most of these (22.0% of new cancer cases and 92% of the 
infections-associated cancers) were indeed attributable to infec-
tions. This is similar to estimates of 22.9% for other developing 
countries; higher than 7.4% estimated for developed countries 
and expectedly higher than global average of 16.1% reported by 
de Martel et al in 2008 (1).
Human papillomavirus infection is one of the most important 
infections-associated with cancers worldwide (37). In 2008, 
700,000 of the 2 million cases of infections-associated cancers 
occurred at sites, such as cervix uteri, anus, penis, vulva, vagina, 
and oropharynx where HPV infections are prevalent. Some 
610,000 of these cancers were attributable to HPV infection and 
490,000 (80.4%) were estimated to have occurred in developing 
countries (37). HPV-associated cancers were the commonest 
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infections-associated cancer in this study. This contrasts with the 
situation in more developed regions of the world and Northeast 
Asia where H. pylori infection is the most common infections-
associated with cancers (1, 7).
Cervical cancer was the most common infections-associated 
cancer in this study and is the second commonest cancer in 
Nigerian women (10). The ASR for cervical cancer in this study 
was 28.3 per 100,000 and that is similar to estimates for West-
Africa (ASR of 29.3 per 100,000) (38) and SSA that ranges from 
20 to 35 per 100,000 (11). Early detection measures are particu-
larly relevant for cervical cancer and population-wide screening 
programs if implemented alongside vaccination with HPV would 
significantly reduce incidence and mortality from cervical cancer 
and other HPV-associated cancers in Nigeria.
Helicobacter pylori infection is associated with stomach 
cancers but these are relatively rare in the Nigerian population. 
The prevalence of stomach cancers in SSA is low with the low-
est incidence rates reported in Western Africa (39), somewhat 
higher rates in Eastern Africa (40) while the highest rates globally 
are seen in Eastern Asia (41). However, given that patients with 
dyspeptic symptoms suspicious of stomach cancer may not be 
adequately investigated due to paucity of endoscopy and biopsy 
services in this environment, the incidence of stomach cancers 
may be under-reported (42).
In our study, liver cancer was the most common infections-
associated cancer in males. Over 75% of liver cancers are hepa-
tocellular carcinomas (HCC) that are largely due to infection 
with HBV and HCV (43), which are endemic in SSA (44, 45). 
There is wide variation in liver cancer incidence rates worldwide 
due to geographic variation in prevalence of chronic HBV and 
HCV infections (43), aflatoxin exposure (46), alcohol-related 
cirrhosis (47), fatty liver disease (48), obesity, and smoking (43). 
In our study, we found ASR of 4.0 per 100,000 in males and 1.1 
per 100,000 in females with a rate ratio of 3.6, similar to findings 
from The Gambia of 1.6 per 100,000 in 2009 (49). Somewhat 
higher incidence rates have been reported from Zimbabwe, 14.4 
per 100,000 and 12.7 per 100,000 in males and females, respec-
tively (rate ratio 1.1) and in Uganda 8.7 per 100,000 and 5.8 per 
100,000 in males and females respectively (rate ratio 1.5) (43). 
The highest liver cancer incidence rates worldwide were reported 
in Eastern Asia although these rates appear to be declining in 
three of the seven countries included in the study namely China, 
the Philippines, and Japan (43).
Human papillomavirus (50) was the first virus shown to be 
associated with human cancer and is linked with several cancers, 
including nasopharyngeal cancers, HL, and NHL (13). In our 
study, the ASR of nasopharyngeal cancers was 1.7 per 100,000 in 
males and 1.5 per 100,000 in females. Although nasopharyngeal 
cancers are rare in many populations, high incidence rates have 
been reported in Northern Africa (51). Other risk factors for 
nasopharyngeal cancers include consumption of salt-preserved 
fish, positive family history, tobacco smoking, and a history of 
chronic respiratory tract conditions (52). Protective factors 
include consumption of fruits and vegetables and possession 
of some human leukocyte antigen (HLA) genotypes that may 
reduce risk (53). NHL is an AIDS defining cancer. However, 
the availability of antiretroviral therapy has largely led to a 
reduction in the risk of NHL in HIV-infected individuals in recent 
times (31).
The increasing availability of antiretroviral therapy has con-
tributed to the reduction in the incidence of KS among HIV posi-
tive individuals in developing countries. KS is an AIDS defining 
cancer that is linked to HIV and HHV8 infections (53). Evidence 
of a strong association exists between KS and immunocompro-
mised individuals because KS risk increases as immune function 
is impaired in HIV-infected individuals (54). The prevalence of 
HHV8 is higher in HIV-infected men who have sex with men 
(MSM) than in heterosexual HIV-infected individuals (53). The 
incidence rates of KS in our study were 1.1 in males and 1.3 in 
females per 100,000. These low rates were similar to findings 
by Bah et  al. in The Gambia (55), and significantly lower than 
incidence rates reported from Zimbabwe 47.2 per 100,000 and 
Uganda 39.3 per 100,000 (55).
Our study has several important limitations. We used cancer 
registry data from two PBCRs in Nigeria because the two other 
PBCR have just been established and did not have data cover-
ing the same period. While we strive to ensure high quality 
of cancer registration in Nigeria, our data may be incomplete 
given the high proportion of morphologically verified cases 
in the databases of the registries that we used. There may be 
under-reporting of cancers that are hard to biopsy because 
of limited diagnostic facilities, and cost of diagnosis and 
treatment. Another limitation is the small sample sizes of the 
few prevalence studies of infectious agents in Nigeria, which 
necessitated the use of data from meta-analyses to estimate our 
PAF. These estimates may not be a true representation of the 
Nigerian population. We did not estimate the incidence of cer-
tain cancers, such as acute T-cell leukemia/lymphoma which is 
associated with HTLV-1 or bile duct cancer which  is associated 
with C. sinensis and O. viverrini because few of these cancers 
were reported by the registries.
In our sensitivity analyses, we found that 35.9% of the 
Nigerian cancer cases reported in GLOBOCAN 2012 database 
were associated with infections and 33.8% were attributable to 
infections. The differences in proportion of cancers attributable 
to infections from our PBCRs and GLOBOCAN 2012 data for 
Nigeria could be due to the fact that the GLOBOCAN 2012 
database contained incidence estimates for only 7 out of the 
12 infections-associated cancers that we considered. Our find-
ings also shows that liver cancer was either over-estimated in 
GLOBOCAN 2012 or under-reported by the PBCRs whose data 
we analyzed in this study. GLOBOCAN 2012 reported ASR of 
7.5 per 100 000 for liver cancer in females and 13.8 per 100,000 
in males, while we found ASR of 2.5 per 100,000 in females and 
3.7 per 100,000 in males.
cOnclUsiOn
Despite these limitations, our study confirms the crucial role 
that infections plays in the etiology of a wide range of cancers 
in the Nigerian population and the opportunities for reducing 
morbidity and mortality through control of these infections. 
Prophylactic vaccination against HPV and HBV, and effective 
management of H. pylori and HCV infections offer tremendous 
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opportunities to significantly reduce the burden of infections-
attributable cancers in Nigeria.
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